Contents
Glaukos $GKOS stock rose 9% in early trading on September 7, 2022, after the company reported positive topline data for iDose TR.
Glaukos Announces Positive Topline Outcomes for Both Phase 3 Pivotal Trials of iDose TR, Achieving Primary Efficacy Endpoints and Demonstrating Favorable Tolerability and Safety Profiles
On September 7, 2022, Glaukos (NYSE: $GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced positive topline data for both Phase 3 pivotal trials of iDose TR that successfully achieved its pre-specified primary efficacy endpoints through 3 months in both Phase 3 trials and demonstrated excellent tolerability and a favorable safety profile through 12 months.
Topline summary results and observations from the iDose TR Phase 3 pivotal trials are as follows:
- For each of the two Phase, 3 iDose TR pivotal trials, GC-010, and GC-012, both the fast- and slow-release iDose TR arms achieved the pre-specified primary efficacy endpoint of non-inferiority to the active comparator arm (twice-daily topical timolol ophthalmic solution, 0.5%) through 3 months.
- For the GC-010 trial, the intraocular pressure (IOP) reductions from baseline over the first three months were 6.6-8.5 mmHg in the slow-release iDose TR arm versus 6.6-7.7 mmHg in the timolol control arm (mmHg range represents IOP reduction means across the six U.S. Food and Drug Administration (FDA) pre-specified timepoints of 8 a.m. and 10 a.m. at Day 10, Week 6 and Month 3). For the GC-012 trial, IOP reductions from baseline over the first three months were 6.7-8.4 mmHg in the slow-release iDose TR arm versus 6.8-7.2 mmHg in the timolol control arm.
- 93% of slow-release iDose TR subjects remained well-controlled on the same or fewer IOP-lowering topical medications at 12 months compared to screening after a single administration of iDose TR, versus 67% of timolol control subjects in both Phase 3 trials. Additionally, in both trials, 81% of slow-release iDose TR subjects were utterly free of IOP-lowering topical medications at 12 months.
- iDose TR demonstrated excellent tolerability, with 98% of slow-release iDose TR subjects continuing in the trial at 12 months versus 95% of timolol control subjects across both Phase 3 trials.
- iDose TR demonstrated a favorable safety profile through 12 months, with no adverse corneal endothelial cell loss, no serious corneal adverse events, and no adverse events of periorbital fat atrophy. Notably, conjunctival hyperemia occurred at a meager rate of 3% for slow-release iDose TR subjects. The most frequent adverse event for slow-release iDose TR subjects was mild transient iritis at a rate of 6% in both Phase 3 trials.
- In-office administration of iDose TR was successfully employed with various subjects across multiple sites with outcomes consistent with the Phase 3 trials, thus demonstrating the feasibility of iDose TR administration in the office setting.
“We are very pleased to announce these robust and replicative positive Phase 3 pivotal data results for iDose TR, which mark a major milestone for our company and powerfully reaffirms our view that iDose TR can be a transformative novel technology able to improve the glaucoma treatment paradigm for patients fundamentally,” said Thomas Burns, Glaukos chairman, and chief executive officer. “We believe there is an important unmet clinical need and strong appetite within the ophthalmic community for safe, effective, and sustained dropless pharmaceutical alternatives to traditional topical medications. These data leave us ideally positioned for an upcoming NDA submission and FDA review for iDose TR as we continue to advance our mission to transform vision for the benefit of patients around the globe suffering from chronic eye diseases.”
Based on the combined efficacy and safety results from both Phase 3 pivotal trials, Glaukos plans to move forward with its plans for an NDA submission to the U.S. FDA for the slow-release iDose TR model, with an expected FDA review and decision completed by the end of 2023.
Administered during a micro-invasive procedure, the iDose TR contains a novel formulation of travoprost, a prostaglandin analog used to reduce IOP. Once all travoprost is released, the iDose TR was designed to be removed and replaced with a new iDose TR, thus potentially offering an alternative to daily eye drop treatment.
The iDose TR Phase 3 clinical program consists of two prospective, randomized, double-masked pivotal clinical trials designed to compare the safety and efficacy of a single administration of one of two iDose TR models with different travoprost release rates (referred to as the fast- and slow-release iDose TR models, respectively) to topical timolol ophthalmic solution, 0.5% BID (twice a day), in reducing elevated IOP in subjects with open-angle glaucoma (OAG) or ocular hypertension. The two iDose TR pivotal trials are nearly identical in design, protocol, predefined endpoints, size, and randomization.
The first of the two Phase 3 pivotal trials, called GC-010, randomized a total of 590 subjects, comprised of 200 subjects in the slow-release iDose TR arm, 197 subjects in the fast-release iDose TR arm, and 193 subjects in the timolol active comparator arm and the second of the two Phase 3 pivotal trials, called GC-012, randomized a total of 560 subjects, comprised of 183 subjects in the slow-release iDose TR arm, 185 subjects in the fast-release iDose TR arm, and 193 subjects in the timolol active comparator arm. In total, the Phase 3 trials randomized a total of 1,150 subjects across 89 clinical sites.
The primary efficacy endpoint of the Phase 3 studies was a non-inferiority comparison to topical timolol 0.5% BID over the first three months, defined as time-matched diurnal IOP measurements at 8 a.m. and 10 a.m. at Day 10, Week 6 and Month 3. Primary safety evaluations were performed for 12 months.
The mean baseline IOP was approximately 24 mmHg across each arm in each study. About 81% of slow-release iDose TR subjects had OAG, while the remaining 19% had ocular hypertension. Approximately 67% of slow-release iDose TR subjects were on one or more IOP-lowering medications at screening, including 23% of subjects on two or more IOP-lowering medications.
Dark Pool Trades Detected In Glaukos $GKOS Stock
Guerilla Stock Trading has detected dark pool trades in Glaukos $GKOS stock.
The dark pool trades on September 2, 2022, look like buy orders to front-run the positive clinical data release on September 7, 2022.
Glaukos $GKOS Chart Technical Analysis
Glaukos $GKOS stock is in a technical strong uptrend. Short-term indicators favor a continuation of the uptrend. The chart pattern shows a big symmetrical triangle breakout test on September 7, 2022.
